杨玉学

【摘要】 目的：研究益生菌聯合莫沙必利治疗便秘型肠易激综合征（ISB-C）的效果。方法：选取笔者所在医院2018年6月-2019年6月ISB-C患者94例，按照随机数字表法将其分为对照组、观察组，各47例。对照组采用莫沙必利治疗，观察组在对照组基础上采用双歧三联活菌胶囊治疗。比较两组临床疗效、治疗前、治疗8周后疼痛程度、血液指标[血浆神经肽Y（NPY）、5-羟色胺（5-HT）、生长抑素（SS）]及不良反应发生情况。结果：观察组治疗总有效率为93.62%，高于对照组的76.60%，差异有统计学意义（P<0.05）。治疗8周后观察组VAS评分低于对照组，差异有统计学意义（P<0.05）。治疗8周后观察组NPY水平高于对照组，5-HT、SS水平低于对照组，差异有统计学意义（P<0.05）。观察组不良反应发生率为4.26%，低于对照组的19.15%，差异有统计学意义（P<0.05）。结论：益生菌联合莫沙必利治疗ISB-C的效果显著，能减轻疼痛程度，改善血液指标，降低不良反应发生率。

【关键词】 益生菌 莫沙必利 便秘型肠易激综合征

doi：10.14033/j.cnki.cfmr.2020.21.015 文献标识码 B 文章编号 1674-6805（2020）21-00-03

Effect of Probiotics Combined with Mosapride on Constipation Irritable Bowel Syndrome/YANG Yuxue. //Chinese and Foreign Medical Research， 2020， 18（21）： -39

[Abstract] Objective： To study the effect of Probiotics combined with Mosapride on constipation irritable bowel syndrome （ISB-C）. Method： A total of 94 patients with ISB-C in our hospital from June 2018 to June 2019 were selected and divided into the control group and the observation group according to the random number table method， with 47 cases in each group. The control group was treated with Mosapride， and the observation group was treated with Bifid Triple Viable Capsules on the basis of the control group. The efficacy， pain level and blood index [plasma neuropeptide Y （NPY）， serotonin （5-HT）， somatostatin （SS）] before treatment and 8 weeks after treatment and adverse reactions were compared. Result： The total effective rate of treatment in the observation group was 93.62%， which was higher than 76.60% in the control group， the difference was statistically significant （P<0.05）. After 8 weeks of treatment， the VAS score in the observation group was lower than that in the control group， the difference was statistically significant （P<0.05）. After 8 weeks of treatment， the level of NPY in the observation group was higher than that in the control group， while the level of 5-HT and SS were lower than those in the control group， the differences were statistically significant （P<0.05）. The incidence of adverse reactions in the observation group was 4.26%， which was lower than 19.15% in the control group， the difference was statistically significant （P<0.05）. Conclusion： Probiotics combined with Mosapride has a significant effect in the treatment of ISB-C， can reduce pain， improve blood index， reduce the incidence of adverse reactions.

[Key words] Probiotics Mosapride Constipation irritable bowel syndrome

First-authors address： Jingshan Renhe Hospital， Jingshan 431899， China

便秘型肠易激综合征（ISB-C）是临床消化内科常见胃肠功能紊乱性疾病，多伴有腹胀腹痛，排便习惯、大便性状改变，病情迁延难愈，较易复发[1]。莫沙必利属于新型促胃肠动力药物，能增强消化道运动，促进胃部排空，改善ISB-C症状，减轻疼痛程度，疗效明确[2-3]。双歧三联活菌是临床常用益生菌类型，能补充肠道菌群，抑制病原菌繁殖，恢复肠道菌群平衡，促进肠道运动，恢复肠胃功能[4]。本研究选取笔者所在医院ISB-C患者94例，旨在探讨益生菌联合莫沙必利的效果，现报告如下。

1 资料与方法

1.1 一般资料

选取笔者所在医院2018年6月-2019年6月ISB-C患者94例，纳入标准：均经隐血实验、大便常规、腹部B超、电子结肠镜等检查确诊为ISB-C。排除标准：心、肝、肾等重要脏器功能障碍;器质性疾病或消化道手术史;治疗前1个月使用过微生物制剂、抗生素、影响胃肠动力药或抗胆碱药物。按照随机数字表法将其分为对照组、观察组，各47例。……